Filament Health and ATMA Journey Centers Announce Licensing Agreement
ATMA will use Filament’s proprietary botanical drug candidate for clinical trials
🎉 Health Canada Provides a No Objection Letter for ATMA’s N500 Phase II Clinical Trial Application
ATMA will use Filament’s proprietary botanical drug candidate for clinical trials
Copyright © 2023 ATMA